The FDA has accepted for review the BLA for lerodalcibep to reduce LDL-C in patients with or high risk of ASCVD and primary hyperlipidemia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback